Exelixis announces results from sub-group analyses of the phase 3 pivotal CELESTIAL trial of cabozantinib for advanced hepatocellular carcinoma presented at ASCO 2018

Access Exelixis’ press release 

© Ipsen Pharma, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France. All rights reserved - 2023